JP2017537940A - 増殖性疾患の処置に有用な融合1,3−アゾール誘導体 - Google Patents

増殖性疾患の処置に有用な融合1,3−アゾール誘導体 Download PDF

Info

Publication number
JP2017537940A
JP2017537940A JP2017531478A JP2017531478A JP2017537940A JP 2017537940 A JP2017537940 A JP 2017537940A JP 2017531478 A JP2017531478 A JP 2017531478A JP 2017531478 A JP2017531478 A JP 2017531478A JP 2017537940 A JP2017537940 A JP 2017537940A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017531478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537940A5 (enExample
Inventor
ケーラー,アンジェラ,エヌ.
ステファン,エリック
カバレロ,フランシスコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2017537940A publication Critical patent/JP2017537940A/ja
Publication of JP2017537940A5 publication Critical patent/JP2017537940A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2017531478A 2014-12-10 2015-12-10 増殖性疾患の処置に有用な融合1,3−アゾール誘導体 Pending JP2017537940A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090290P 2014-12-10 2014-12-10
US62/090,290 2014-12-10
PCT/US2015/065044 WO2016094688A1 (en) 2014-12-10 2015-12-10 Fused 1,3-azole derivatives useful for the treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
JP2017537940A true JP2017537940A (ja) 2017-12-21
JP2017537940A5 JP2017537940A5 (enExample) 2019-02-07

Family

ID=55073117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017531478A Pending JP2017537940A (ja) 2014-12-10 2015-12-10 増殖性疾患の処置に有用な融合1,3−アゾール誘導体

Country Status (6)

Country Link
US (2) US10017520B2 (enExample)
EP (1) EP3230279A1 (enExample)
JP (1) JP2017537940A (enExample)
AU (1) AU2015360416A1 (enExample)
CA (1) CA2968884A1 (enExample)
WO (1) WO2016094688A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3377488T3 (da) 2015-11-19 2022-10-03 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
SG10202005790VA (en) 2015-12-22 2020-07-29 Incyte Corp Heterocyclic compounds as immunomodulators
CN109071456A (zh) 2016-02-16 2018-12-21 麻省理工学院 作为myc调节剂的max结合剂及其用途
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
MA45116A (fr) 2016-05-26 2021-06-02 Incyte Corp Composés hétérocycliques comme immunomodulateurs
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
GB201614134D0 (en) * 2016-08-18 2016-10-05 Glaxosmithkline Ip Dev Ltd Novel compounds
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
EP3558985B1 (en) 2016-12-22 2022-09-07 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
MD3558990T2 (ro) 2016-12-22 2023-02-28 Incyte Corp Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1
HRP20230090T1 (hr) 2018-03-30 2023-03-17 Incyte Corporation Heterociklički spojevi kao imunomodulatori
PT3790877T (pt) 2018-05-11 2023-05-10 Incyte Corp Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1
TWI827677B (zh) 2018-09-18 2024-01-01 美商尼坎醫療公司 作為src同源-2磷酸酶抑制劑之稠合三環衍生物
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
AR119624A1 (es) 2019-08-09 2021-12-29 Incyte Corp Sales de un inhibidor de pd-1 / pd-l1
MX2022003578A (es) 2019-09-30 2022-05-30 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores.
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
US20230150956A1 (en) * 2020-02-10 2023-05-18 Stemsynergy Therapeutics, Inc. Myc inhibitors and uses thereof
BR112022022409A2 (pt) 2020-05-06 2023-02-07 Ajax Therapeutics Inc 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
CR20230230A (es) 2020-11-06 2023-07-27 Incyte Corp Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049632A1 (en) * 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
WO2002051409A1 (en) * 2000-12-22 2002-07-04 Geron Corporation Telomerase inhibitors and methods of their use
JP2009501778A (ja) * 2005-07-20 2009-01-22 アバンテイス・フアルマ・エス・アー 1,4−ジヒドロピリジン縮合ヘテロ環、これらの調製法、使用およびこれらを含有する組成物
WO2011063602A1 (zh) * 2009-11-27 2011-06-03 华东理工大学 5-取代-2,4-噻唑烷二酮类化合物在制备igf1r功能调节药物中的应用
WO2012033149A1 (ja) * 2010-09-10 2012-03-15 塩野義製薬株式会社 Ampk活性化作用を有するヘテロ環縮合イミダゾール誘導体
JP2012508260A (ja) * 2008-11-10 2012-04-05 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼの阻害剤として有用な化合物
JP2013512903A (ja) * 2009-12-04 2013-04-18 サイリーン ファーマシューティカルズ インコーポレーティッド Ck2阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
WO2014159837A1 (en) * 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02191695A (ja) 1989-01-20 1990-07-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02194085A (ja) 1989-01-24 1990-07-31 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02196887A (ja) 1989-01-26 1990-08-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02208392A (ja) 1989-02-08 1990-08-17 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02222488A (ja) 1989-02-23 1990-09-05 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227489A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227490A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227491A (ja) 1989-03-01 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02242882A (ja) 1989-03-16 1990-09-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247280A (ja) 1989-03-20 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247282A (ja) 1989-03-22 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255794A (ja) 1989-03-29 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255793A (ja) 1989-03-30 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
US5965574A (en) 1996-08-13 1999-10-12 Chen; Yuhpyng Liang Heteroaryl amines as novel acetylcholinesterase inhibitors
JPH08231541A (ja) 1995-03-01 1996-09-10 Nippon Soda Co Ltd イミダゾリン誘導体および除草剤
WO2000018746A1 (en) * 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
JP2003057783A (ja) 2001-08-21 2003-02-26 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075955A (ja) 2001-09-03 2003-03-12 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075957A (ja) 2001-09-07 2003-03-12 Konica Corp スケイル模様のない光熱写真画像形成材料
CN1558762A (zh) * 2001-09-14 2004-12-29 ŵ��Ų�ڿ˹�˾ R-态胰岛素六聚物的HisB10Zn2+位点的新配体
US20050042674A9 (en) * 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
GB2387172A (en) * 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
EP1501509A4 (en) * 2002-04-30 2009-07-15 Merck & Co Inc ARYL-LINK-ARYL-SUBSTITUTED THIAZOLIDIN-DION- AND OXAZOLIDIN-DION AS SODIUM CHANNEL BLOCKER
JP4211433B2 (ja) 2002-08-14 2009-01-21 三菱化学株式会社 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子
WO2004080989A1 (ja) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited フラン化合物の製造方法
US7777051B2 (en) 2003-05-13 2010-08-17 Icagen, Inc. Asymmetric benzimidazoles and related compounds as potassium channel modulators
CA2538759C (en) 2003-09-12 2015-11-03 Elixir Pharmaceuticals, Inc. Substituted heterocyclic compounds as sirtuin inhitibitors
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US7842941B2 (en) 2003-10-06 2010-11-30 Sumitomo Chemical Company, Limited Aromatic compound
EP1768694A1 (en) * 2004-07-09 2007-04-04 Novo Nordisk A/S Phamaceutical preparations comprising insulin
JP2006084592A (ja) 2004-09-14 2006-03-30 Fuji Photo Film Co Ltd 感光性組成物
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
JP4931434B2 (ja) 2006-02-14 2012-05-16 株式会社ダイセル アミノ基含有アダマンタン誘導体とその製造方法
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
WO2008012010A1 (en) 2006-07-27 2008-01-31 Ucb Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS
US20100292188A1 (en) 2008-01-24 2010-11-18 Ucb Pharma S.A. Compounds Comprising A Cyclobutoxy Group
US8133695B2 (en) 2008-02-28 2012-03-13 Life Technologies Corporation Fluorescence polarization hERG assay
US8865909B2 (en) * 2008-11-20 2014-10-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-biofilm agents
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
JP5046213B2 (ja) 2009-03-12 2012-10-10 独立行政法人科学技術振興機構 光学活性アルコール化合物の製法
JPWO2012153780A1 (ja) 2011-05-11 2014-07-31 出光興産株式会社 新規化合物、有機エレクトロルミネッセンス素子用材料及び有機エレクトロルミネッセンス素子
KR20140060484A (ko) 2011-09-13 2014-05-20 이데미쓰 고산 가부시키가이샤 축합 복소 방향족 유도체, 유기 전계 발광 소자용 재료 및 그것을 이용한 유기 전계 발광 소자
JP6653573B2 (ja) 2012-05-22 2020-02-26 トラスティーズ・オブ・ダートマウス・カレッジ シクロアルカニル[b]インドール、シクロアルカニル[b]ベンゾフラン、シクロアルカニル[b]ベンゾチオフェンを合成するための方法、化合物および使用の方法
JP6418151B2 (ja) 2013-02-28 2018-11-07 住友化学株式会社 縮合複素環化合物及びその有害生物防除用途
US9242944B2 (en) 2013-03-27 2016-01-26 University Of Maryland, Baltimore Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability
EP3082812A4 (en) 2013-12-11 2017-04-26 The Scripps Research Institute Small molecule c-myc inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049632A1 (en) * 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
WO2002051409A1 (en) * 2000-12-22 2002-07-04 Geron Corporation Telomerase inhibitors and methods of their use
JP2009501778A (ja) * 2005-07-20 2009-01-22 アバンテイス・フアルマ・エス・アー 1,4−ジヒドロピリジン縮合ヘテロ環、これらの調製法、使用およびこれらを含有する組成物
JP2012508260A (ja) * 2008-11-10 2012-04-05 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼの阻害剤として有用な化合物
WO2011063602A1 (zh) * 2009-11-27 2011-06-03 华东理工大学 5-取代-2,4-噻唑烷二酮类化合物在制备igf1r功能调节药物中的应用
JP2013512903A (ja) * 2009-12-04 2013-04-18 サイリーン ファーマシューティカルズ インコーポレーティッド Ck2阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
WO2012033149A1 (ja) * 2010-09-10 2012-03-15 塩野義製薬株式会社 Ampk活性化作用を有するヘテロ環縮合イミダゾール誘導体
WO2014159837A1 (en) * 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, JPN6019036133, 2014, pages 5693 - 5701, ISSN: 0004268792 *
NATURE CHEMICAL BIOLOGY, vol. 1(3), JPN6019036150, 2005, pages 167 - 173, ISSN: 0004268805 *
PLOS ONE, vol. 8(4), JPN6019036148, 2013, pages 1 - 9, ISSN: 0004268804 *
REGISTRY(STN), JPN7019003003, 2001, ISSN: 0004268793 *
REGISTRY(STN), JPN7019003006, 2004, ISSN: 0004268794 *
REGISTRY(STN), JPN7019003007, 2002, ISSN: 0004268795 *
REGISTRY(STN), JPN7019003008, 2002, ISSN: 0004268796 *
REGISTRY(STN), JPN7019003009, 2003, ISSN: 0004268798 *
REGISTRY(STN), JPN7019003010, 2002, ISSN: 0004268799 *
REGISTRY(STN), JPN7019003011, 2002, ISSN: 0004268800 *
REGISTRY(STN), JPN7019003012, 2002, ISSN: 0004268801 *
REGISTRY(STN), JPN7019003013, 2001, ISSN: 0004268802 *
REGISTRY(STN), JPN7019003014, 2013, ISSN: 0004268806 *
REGISTRY(STN), JPN7019003015, 2004, ISSN: 0004268808 *
REGISTRY(STN), JPN7019003016, 2013, ISSN: 0004268809 *
REGISTRY(STN), JPN7019003017, 2013, ISSN: 0004268810 *
REGISTRY(STN), JPN7019003018, 2011, ISSN: 0004268811 *
REGISTRY(STN), JPN7019003019, 2002, ISSN: 0004268812 *
REGISTRY(STN), JPN7019003020, 2004, ISSN: 0004268797 *
SYNTHETIC COMMUNICATIONS, vol. 43(14), JPN6019036147, 2013, pages 1882 - 1895, ISSN: 0004268803 *
TETRAHEDRON LETTERS, vol. 52, JPN6019036155, 2011, pages 3347 - 3352, ISSN: 0004268807 *

Also Published As

Publication number Publication date
AU2015360416A1 (en) 2017-06-08
US20160168165A1 (en) 2016-06-16
CA2968884A1 (en) 2016-06-16
US20200048276A9 (en) 2020-02-13
EP3230279A1 (en) 2017-10-18
US10017520B2 (en) 2018-07-10
WO2016094688A1 (en) 2016-06-16
US20180291035A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
JP2017537940A (ja) 増殖性疾患の処置に有用な融合1,3−アゾール誘導体
US11932625B2 (en) Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
JP6854762B2 (ja) サイクリン依存性キナーゼ7(cdk7)の阻害剤
JP7308146B2 (ja) インターロイキン1受容体関連キナーゼの阻害剤およびその使用
JP6861166B2 (ja) サイクリン依存性キナーゼの阻害剤
US12415816B2 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CN113993519B (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
JP2017512186A (ja) ジヒドロプテリジノン誘導体およびその使用
JP6788583B2 (ja) 増殖性疾患を処置するためのチアゾリル含有化合物
JP2018522867A (ja) 縮合二環式ピリミジン誘導体およびこれらの使用
US10865213B2 (en) Max binders as MYC modulators and uses thereof
JP2020529998A (ja) 血漿カリクレインの阻害剤およびその使用
JP2021514955A (ja) プロテアソーム関連ユビキチン受容体rpn13機能を阻止する低分子およびその使用法
JP2021529174A (ja) Dot1lディグレーダーおよびその使用
JP7185631B2 (ja) 抗線維化化合物
US20230382865A1 (en) Histone demethylase 5 inhibitors and uses thereof
US20230339865A1 (en) Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases
WO2017151625A1 (en) 4,9-dioxo-4,9-dihydronaphtho(2,3-b)furan-3-carboxmide derivatives and uses thereof for treating proliferative diseases and infectious diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200526